PT Perspective Therapeutics, Inc. Stock: price and insider trades · United States · SEC (Form 4)Source id SEC:perspective-therapeutics-inc-1cf74f US · SEC (Form 4) Mcap US$342.1M Track the Perspective Therapeutics, Inc. stock price and the full insider trade history of the company, a listed equity based in United States. Shares trade on the US market, under the supervision of SEC (Form 4). Market capitalisation: €342.1m. The latest transaction was disclosed on 17 November 2025 (Acquisition). Among the most active insiders: Williamson Robert F III. All data is accessible without an account.
Analyst consensus: bullish or bearish? Analysts rate Perspective Therapeutics, Inc. Strong Buy (bullish), based on 14 analysts. Average price target: US$12.79.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ Sigma AI Analysis Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 17 November 2025
All Executives30 Thresholds0 Prospectus0 Other0
Declarations 30 total
▲ Chief Accounting Officer · Executives · 13 Nov 2025
11,000 shares @ US$2.0268 23.0% of flow Common Stock SEC:0001193125-25-283953:0
Canonical exit: 11 Feb 2026 (T+90) ▲ Director · Executives · 12 Nov 2025
9,498 shares @ US$2.10 8.8% of flow Common Stock SEC:0001193125-25-281626:0
Canonical exit: 10 Feb 2026 (T+90) ▲ Chief Financial Officer · Executives · 28 Mar 2025
33,333 shares @ US$2.2484 100.0% of flow Common Stock SEC:0000950170-25-048696:0
Canonical exit: 26 Jun 2025 (T+90) ▲ Director · Executives · 28 Mar 2025
22,192 shares @ US$2.27 26.0% of flow Common Stock SEC:0000950170-25-048698:0
Canonical exit: 26 Jun 2025 (T+90) ▲ Director · Executives · 31 Mar 2025
23,475 shares @ US$2.1299 19.6% of flow Common Stock SEC:0000950170-25-048691:0
Canonical exit: 29 Jun 2025 (T+90) ▲ Chief Executive Officer · Executives · 28 Mar 2025
22,026 shares @ US$2.2421 19.4% of flow Common Stock SEC:0000950170-25-048775:0
Canonical exit: 26 Jun 2025 (T+90) ▲ Director · Executives · 4 Dec 2024
25,975 shares @ US$3.85 100.0% of flow Common Stock SEC:0000950170-24-134067:0
Canonical exit: 4 Mar 2025 (T+90) ▲ CEO · Executives · 4 Dec 2024
8,000 shares @ US$3.7665 12.1% of flow Common Stock SEC:0000950170-24-133355:0
Canonical exit: 4 Mar 2025 (T+90) ▲ Director · Executives · 25 Nov 2024
3,647 shares @ US$3.6199 7.0% of flow Common Stock SEC:0000950170-24-131251:0
Canonical exit: 23 Feb 2025 (T+90) ▲ Chief Financial Officer · Executives · 25 Nov 2024
400 shares @ US$3.55 2.1% of flow Common Stock SEC:0000950170-24-131250:0
Canonical exit: 23 Feb 2025 (T+90) ▲ CEO · Executives · 25 Nov 2024
14,500 shares @ US$3.784 22.2% of flow Common Stock SEC:0000950170-24-130754:0
Canonical exit: 23 Feb 2025 (T+90) ▲ Chief Financial Officer · Executives · 17 Jun 2024
1,800 shares @ US$9.815 25.6% of flow Common Stock SEC:0000950170-24-074594:0
Canonical exit: 15 Sept 2024 (T+90) ▲ Director · Executives · 14 Jun 2024
4,504 shares @ US$10.90 19.4% of flow Common Stock SEC:0000950170-24-074592:0
Canonical exit: 12 Sept 2024 (T+90) ▲ CEO · Executives · 13 Jun 2024
100,000 shares @ US$1.1743 46.3% of flow Common Stock SEC:0000950170-24-073145:0
Canonical exit: 11 Sept 2024 (T+90) ▲ Director · Executives · 3 Jun 2024
34,246 shares @ US$1.4598 19.4% of flow Common Stock SEC:0000950170-24-068638:0
Canonical exit: 1 Sept 2024 (T+90) ▲ Director · Executives · 31 May 2024
55,000 shares @ US$1.38 39.1% of flow Common Stock SEC:0000950170-24-067945:0
Canonical exit: 29 Aug 2024 (T+90) ▲ Chief Financial Officer · Executives · 31 May 2024
13,006 shares @ US$1.3999 26.1% of flow Common Stock SEC:0000950170-24-067953:0
Canonical exit: 29 Aug 2024 (T+90) ▲ Director · Executives · 29 May 2024
11,375 shares @ US$1.32 7.8% of flow Common Stock SEC:0000950170-24-066557:0
Canonical exit: 27 Aug 2024 (T+90) ◇ VP Finance/Prin Fin&Acct Offic · Executives · 23 Apr 2024
30,000 shares @ US$0.36 100.0% of flow Common stock SEC:0000950170-24-047645:0
60,431,039 shares @ US$0.95 100.0% of flow Common Stock SEC:0000950170-24-028446:0
Canonical exit: 4 Jun 2024 (T+90) ▲ Director · Executives · 30 Jan 2024
18,579 shares @ US$0.71 6.8% of flow Common Stock SEC:0001437749-24-002837:0
Canonical exit: 29 Apr 2024 (T+90) ▲ Director · Executives · 26 Jan 2024
12,250 shares @ US$0.61 3.8% of flow Common Stock SEC:0001437749-24-002571:0
Canonical exit: 25 Apr 2024 (T+90) ▲ Director · Executives · 24 Jan 2024
29,862 shares @ US$0.49 7.5% of flow Common Stock SEC:0001437749-24-002322:0
Canonical exit: 23 Apr 2024 (T+90) ▲ Chief Medical Officer · Executives · 24 Jan 2024
280,000 shares @ US$0.4996 79.6% of flow Common Stock SEC:0001437749-24-002324:0
Canonical exit: 23 Apr 2024 (T+90) ▲ Director · Executives · 21 Dec 2023
3,663 shares @ US$0.3283 0.6% of flow Common Stock SEC:0001437749-23-035321:0
Canonical exit: 20 Mar 2024 (T+90) 25 of 30 declarations
Load more (5 remaining) About Perspective Therapeutics, Inc. Perspective Therapeutics, Inc. is a company focused on developing innovative cancer treatments. It is listed on the XNAS market.